Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Eur Radiol. 2020 Oct;30(10):5437-5445. doi: 10.1007/s00330-020-06812-x. Epub 2020 May 7.
To evaluate at which sensitivity digital breast tomosynthesis (DBT) would become cost-effective compared to digital mammography (DM) in a population breast cancer screening program, given a constant estimate of specificity.
In a microsimulation model, the cost-effectiveness of biennial screening for women aged 50-75 was simulated for three scenarios: DBT for women with dense breasts and DM for women with fatty breasts (scenario 1), DBT for the whole population (scenario 2) or maintaining DM screening (reference). For DM, sensitivity was varied depending on breast density from 65 to 87%, and for DBT from 65 to 100%. The specificity was set at 96.5% for both DM and DBT. Direct medical costs were considered, including screening, biopsy and treatment costs. Scenarios were considered to be cost-effective if the incremental cost-effectiveness ratio (ICER) was below €20,000 per life year gain (LYG).
For both scenarios, the ICER was more favourable at increasing DBT sensitivity. Compared with DM screening, 0.8-10.2% more LYGs were found when DBT sensitivity was at least 75% for scenario 1, and 4.7-18.7% when DBT sensitivity was at least 80% for scenario 2. At €96 per DBT, scenario 1 was cost-effective at a DBT sensitivity of at least 90%, and at least 95% for scenario 2. At €80 per DBT, these values decreased to 80% and 90%, respectively.
DBT is more likely to be a cost-effective alternative to mammography in women with dense breasts. Whether DBT could be cost-effective in a general population highly depends on DBT costs.
• DBT could be a cost-effective screening modality for women with dense breasts when its sensitivity is at least 90% at a maximum cost per screen of €96. • DBT has the potential to be cost-effective for screening all women when sensitivity is at least 90% at a maximum cost per screen of €80. • Whether DBT could be used as an alternative to mammography for screening all women is highly dependent on the cost of DBT per screen.
在给定特定不变的特异性的情况下,评估数字乳腺断层摄影术(DBT)相对于数字乳腺摄影术(DM)在人群乳腺癌筛查计划中的灵敏度达到何种程度具有成本效益。
在微模拟模型中,对 50-75 岁女性进行两年一次的筛查,模拟三种情况:致密乳腺的女性进行 DBT 检查,脂肪乳腺的女性进行 DM 检查(方案 1),全人群进行 DBT 检查(方案 2)或维持 DM 筛查(参考)。DM 的灵敏度根据乳腺密度从 65%变化到 87%,而 DBT 的灵敏度从 65%变化到 100%。DM 和 DBT 的特异性均设定为 96.5%。考虑了直接医疗成本,包括筛查、活检和治疗成本。如果增量成本效益比(ICER)低于每获得 1 个生命年(LYG)的 20,000 欧元,则认为方案具有成本效益。
对于这两种情况,随着 DBT 灵敏度的增加,ICER 更有利。与 DM 筛查相比,方案 1 中 DBT 灵敏度至少为 75%时,可多获得 0.8-10.2%的 LYG,方案 2 中 DBT 灵敏度至少为 80%时,可多获得 4.7-18.7%的 LYG。当 DBT 价格为 96 欧元时,方案 1 的 DBT 灵敏度至少为 90%具有成本效益,方案 2 的 DBT 灵敏度至少为 95%具有成本效益。当 DBT 价格为 80 欧元时,这些值分别降低至 80%和 90%。
对于致密乳腺的女性,DBT 作为乳腺 X 线摄影术的一种更具成本效益的替代方法。DBT 是否可在一般人群中具有成本效益,高度取决于 DBT 的成本。
当 DBT 的灵敏度最高时,每屏成本不超过 96 欧元,且至少为 90%,则 DBT 可能成为致密乳腺女性具有成本效益的筛查方法。
当 DBT 的灵敏度最高时,每屏成本不超过 80 欧元,且至少为 90%,则 DBT 可能成为所有女性具有成本效益的筛查方法。
DBT 是否可用于替代所有女性的乳腺 X 线摄影术筛查,高度取决于 DBT 的每屏成本。